Roger Paredes

Roger Paredes, MD, PhD, is Head of the Infectious Diseases Department at the Hospital Germans Trias i Pujol and Principal Investigator of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. He obtained his MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB) and specialised in HIV research at the Brigham & Women’s Hospital, Harvard Medical School, supported by a "la Caixa" grant for postgraduate studies. His team at irsiCaixa has demonstrated the clinical utility of HIV-1 deep sequencing in both high- and low-income countries. Currently, he leads pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation.

Dr. Paredes coordinates the 10 million-euro H2020 EU grant MISTRAL (GA- 847943) and is co-PI in 3 grants from the Canadian Institutes of Health Research aimed at disentangling the role of the human microbiome on HIV pathogenesis, transmission and associated cancers. 

Since the COVID-19 pandemic, Dr Paredes has been the Spanish National Coordinator of seminal NIH/NIAID-funded randomized clinical trials, including ACTT-1 and 2 and the ACTIV-3/TICO and STRIVE platforms, which have defined the current standard of care for this disease in hospitalized patients as well as in outpatients. His department hosts the largest Long COVID Unit in Spain.

Dr. Paredes is member of the WHO HIV Drug Resistance Strategy (ResNet) Steering Committee, the WHO HIV treatment guidelines group, and the WHO Clinical Network on COVID-19. He is coauthor of the Spanish HIV (GESIDA) and COVID-19 (SEIMC) treatment guidelines and is member of the IAS-USA HIV Drug resistance group. He is Adjunct Associate Professor of the Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH and the Chair of Infectious Diseases and Immunity at the University of Vic-University of Central Catalonia (UVic-UCC).